Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation

Yuan Liang Zhang, Jie Wen Sun, Yin Yin Xie, Yan Zhou, Ping Liu, Jia Chun Song, Chun Hui Xu, Lan Wang, Dan Liu, Ai Ning Xu, Zhu Chen, Sai Juan Chen, Xiao Jian Sun, Qiu Hua Huang

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

The histone H3 lysine 36 methyltransferase SETD2 is frequently mutated in various cancers, including leukemia. However, there has not been any functional model to show the contribution of SETD2 in hematopoiesis or the causal role of SETD2 mutation in tumorigenesis. In this study, using a conditional Setd2 knockout mouse model, we show that Setd2 deficiency skews hematopoietic differentiation and reduces the number of multipotent progenitors; although the number of phenotypic hematopoietic stem cells (HSCs) in Setd2-deleted mice is unchanged, functional assays, including serial BM transplantation, reveal that the self-renewal and competitiveness of HSCs are impaired. Intriguingly, Setd2-deleted HSCs, through a latency period, can acquire abilities to overcome the growth disadvantage and eventually give rise to hematopoietic malignancy characteristic of myelodysplastic syndrome. Gene expression profile of Setd2-deleted hematopoietic stem/progenitor cells (HSPCs) partially resembles that of Dnmt3a/Tet2 double knockout HSPCs, showing activation of the erythroid transcription factor Klf1-related pathway, which plays an important role in hematopoietic malignant transformation. Setd2 deficiency also induces DNA replication stress in HSCs, as reflected by an activated E2F gene regulatory network and repressed expression of the ribonucleotide reductase subunit Rrm2b, which results in proliferation and cell cycle abnormalities and genomic instability, allowing accumulation of secondary mutation(s) that synergistically contributes to tumorigenesis. Thus, our results demonstrate that Setd2 is required for HSC self-renewal, and provide evidence supporting the causal role of Setd2 deficiency in tumorigenesis. The underlying mechanism shall advance our understanding of epigenetic regulation of cancer and provide potential new therapeutic targets.

Original languageEnglish (US)
Pages (from-to)476-490
Number of pages15
JournalCell Research
Volume28
Issue number4
DOIs
StatePublished - Apr 1 2018

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation'. Together they form a unique fingerprint.

  • Cite this

    Zhang, Y. L., Sun, J. W., Xie, Y. Y., Zhou, Y., Liu, P., Song, J. C., Xu, C. H., Wang, L., Liu, D., Xu, A. N., Chen, Z., Chen, S. J., Sun, X. J., & Huang, Q. H. (2018). Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation. Cell Research, 28(4), 476-490. https://doi.org/10.1038/s41422-018-0015-9